Eli Lilly and Company (NYSE:LLY) - Equities researchers at Truist Securiti issued their FY2025 EPS estimates for shares of Eli Lilly and in a report issued on Monday, January 11th. Truist Securiti analyst G. Gilbert expects that the company will earn $13.85 per share for the year. Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Sunday, November 1st. The company reported $1.54 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $1.71 by ($0.17). Eli Lilly and had a return on equity of 166.45% and a net margin of 24.01%. The business had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.87 billion. During the same quarter last year, the business posted $1.48 EPS. The company's quarterly revenue was up 4.8% on a year-over-year basis.
A number of other research firms also recently weighed in on LLY. Truist raised their price target on Eli Lilly and from $182.00 to $200.00 in a research report on Tuesday. Berenberg Bank initiated coverage on Eli Lilly and in a report on Tuesday, September 29th. They issued a "hold" rating and a $144.00 price objective on the stock. Mizuho lifted their price objective on Eli Lilly and from $156.00 to $164.00 and gave the stock a "neutral" rating in a report on Wednesday, December 16th. Wolfe Research upgraded Eli Lilly and from a "peer perform" rating to an "outperform" rating and lifted their price objective for the stock from $147.00 to $183.00 in a report on Thursday, December 10th. Finally, BidaskClub raised Eli Lilly and from a "strong sell" rating to a "sell" rating in a research note on Friday, December 11th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company's stock. The company presently has a consensus rating of "Buy" and a consensus price target of $171.13.
NYSE LLY opened at $179.41 on Wednesday. The stock's 50-day simple moving average is $161.18 and its two-hundred day simple moving average is $153.42. Eli Lilly and has a twelve month low of $117.06 and a twelve month high of $189.30. The company has a quick ratio of 1.06, a current ratio of 1.36 and a debt-to-equity ratio of 3.27. The company has a market capitalization of $171.62 billion, a price-to-earnings ratio of 29.22, a PEG ratio of 1.52 and a beta of 0.34.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tatro Capital LLC purchased a new stake in Eli Lilly and during the 4th quarter worth approximately $259,000. Brookstone Capital Management increased its holdings in shares of Eli Lilly and by 8.9% in the 4th quarter. Brookstone Capital Management now owns 14,435 shares of the company's stock valued at $2,437,000 after purchasing an additional 1,184 shares in the last quarter. Mountain Capital Investment Advisors Inc purchased a new position in shares of Eli Lilly and in the 4th quarter valued at about $252,000. First Hawaiian Bank increased its holdings in Eli Lilly and by 31.7% during the 4th quarter. First Hawaiian Bank now owns 5,447 shares of the company's stock valued at $920,000 after acquiring an additional 1,310 shares in the last quarter. Finally, Wallington Asset Management LLC increased its holdings in Eli Lilly and by 9.0% during the 4th quarter. Wallington Asset Management LLC now owns 5,038 shares of the company's stock valued at $850,000 after acquiring an additional 417 shares in the last quarter. 69.85% of the stock is owned by institutional investors.
In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the firm's stock in a transaction on Monday, January 11th. The shares were sold at an average price of $185.49, for a total transaction of $40,807,800.00. Following the completion of the transaction, the insider now owns 111,003,815 shares of the company's stock, valued at $20,590,097,644.35. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.09% of the stock is currently owned by company insiders.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 10th. Stockholders of record on Friday, February 12th will be paid a dividend of $0.85 per share. The ex-dividend date of this dividend is Thursday, February 11th. This is an increase from Eli Lilly and's previous quarterly dividend of $0.74. This represents a $3.40 dividend on an annualized basis and a dividend yield of 1.90%. Eli Lilly and's dividend payout ratio (DPR) is currently 49.01%.
About Eli Lilly and
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia.
Recommended Story: Profit Margin
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Stocks to Sell Before the New Year
We’re officially in the holiday season, which means it’s time to get our portfolios set for the new year. And for many investors, 2021 can’t get here fast enough. Don’t get me wrong. Overall, being invested in stocks has been a wise move. But it hasn’t been without its ups and downs. For investors to profit in this market, they have had to have conviction.
But having conviction also means knowing when it’s time to sell. One of the hardest things to do in life, as well as in investing, is to let go of an idea that simply isn’t working. There are a lot of story stocks out there. And while those stories may turn out to be more than fairy tales, in the long run, it doesn’t mean you have to pay tomorrow’s prices today.
Or, it could simply be a good time to take some profits. A new administration in Washington D.C. will bring a different, and most likely less favorable, tax policy regarding capital gains. It may be advantageous to take some of your gains now.
Whatever your motivation may be, we’ve put together a list of seven stocks that you should consider selling before the new year.
View the "7 Stocks to Sell Before the New Year".